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Abstract: The safety and precision of peptide antigens has prompted the search for adjuvants 
capable of increasing the immune response against these intrinsically poorly immunogenic 
antigens. The integration of both immunostimulants and peptide antigens within nanometric 
delivery systems for their co-delivery to immune cells is a promising vaccination strategy. 
With this in mind, the potential synergistic effect of the immunostimulant poly (I:C) (pIC) 
and a T-Helper peptide (PADRE), integrated into a chitosan (CS) based nanostructure, was 
explored. The value of this nanostructured combination of materials was assessed for a 
peptide antigen (1338aa) derived from the HPV-16 L2 protein. These nanoparticles, produced 
by ionic gelation technique, exhibited a nanometric size (<300 nm), a high positive surface 
charge (>40 mV) and high pIC association efficiency (>96%). They also showed capacity 
for the association of both the 1338aa and PADRE peptides. The influence of the presence 
of pIC and PADRE in the nanocomposition, as well as that of the peptide presentation form 
(encapsulated versus surface adsorbed) on the antibody induction was evaluated in a 
preliminary in vivo study. The data obtained highlights the possibility to engineer nanoparticles 
through the rational combination of a number of adjuvant molecules together with the antigen. 
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The advent of synthetic peptide-based antigens has brought new opportunities and also new challenges to 
the development of effective vaccines. These synthetic and chemically well-defined molecules, designed 
from known epitopes of tumor cells and pathogens, present no risk of mutation or reversion associated 
to whole pathogen-based vaccines. From the technological point of view, they are easy to produce under 
appropriate quality control practices [1] and present little risk of contamination by pathogenic or toxic 
substances [2]. However, due to their purity, these entities lack “danger signals” [3] and consequently 
are incapable of activating immune cells. Furthermore, peptide-based antigens present, in general, 
limited major histocompatibility complex (MHC) recognition, which contributes to their poor intrinsic 
immunogenicity [4]. Therefore, there is a need to design adjuvant systems specifically adapted to 
facilitate the efficient presentation of peptide-based antigens without compromising their favorable safety 
profile. Within this context, nanoparticles made of biodegradable polymers are receiving increasing attention. 
Among the different nanotechnology-based adjuvant systems, nanoparticles made of chitosan (CS), 
a biodegradable polysaccharide [5], are particularly attractive since these nanoparticles have already 
proven to be efficient adjuvant systems for a variety of protein antigens [6,7]. In addition to their capacity 
for associating with peptides and proteins, CS nanoparticles are well known for their ability to efficiently 
complex polynucleotides, protect them from enzyme degradation, and deliver them to cells [8]. Therefore, 
in principle, such delivery systems could offer the possibility of associating simultaneously antigens and 
polynucleotide-based immunostimulants and delivering them to the target site in a controlled manner. 
As a model peptide-based antigen that would potentially benefit from the chitosan-based nanotechnology, 
we have chosen the peptide (1338aa), which comprises a specific amino sequence (13–38aa) from the 
Human Papillomavirus 16 (HPV-16) L2 capsid protein. Currently available HPV vaccines are based on 
the L1 protein from the HPV capsid that self assembles into virus-like particles (VLPs) [9]. These 
vaccines induce high levels of type-specific neutralizing antibodies, however, these antibodies have a 
limited ability to protect against other oncogenic HPV types [10,11]. On the other hand, the L2 minor 
capsid protein does not assemble into VLPs and is less immunogenic but it contains conserved domains 
that elicit broad cross-type neutralizing antibodies [12], which makes L2 a potential target for a novel 
HPV vaccine. The amino acid sequence 17–36aa of this protein has been identified as a highly conserved 
neutralizing epitope among the HPV strains [13] and so has great potential as an antigen for a broadly 
cross-protective HPV vaccine. 
In order to enhance the adjuvant properties of chitosan nanoparticles, the immunostimulant 
Polyinosinic-polycytidylic acid—poly (I:C) (pIC), a synthetic analog of viral double-stranded RNA 
(dsRNA), was incorporated into the nanostructure. This compound mimics a molecular pattern 
associated with viral infections and it is an agonist of the Toll-like receptor 3 (TLR3), present in the 
endosomes of antigen-presenting cells (APC). The activation of TLR3 promotes dendritic cell maturation 
and the production of T cell chemokines [14], thereby potentiating both humoral and cellular immune 
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responses [15,16]. Nevertheless, the systemic delivery of pIC can also provoke adverse effects, such as 
autoimmunity [17] and chronic inflammatory diseases [18], as observed in rodent models. In the context 
of this work, it was hypothesized that the incorporation of this immunostimulant into CS nanoparticles 
could protect it from degradation and facilitate its uptake by the APCs, consequently leading to a 
reduction of its effective dose [19,20]. 
Finally, in addition to the HPV L2 antigenic peptide and the pIC immunostimulant, a T-Helper Pan 
HLA-DR epitope (PADRE) peptide was associated with the composition. This peptide can bind to the 
majority of MHC class II alleles [21] and has previously been shown to increase the immune response 
to associated peptide-based antigens [22,23]. Accordingly, the inclusion of the PADRE peptide in the 
nanoparticle is expected to provide linked T cell helper functions to the 1338aa peptide and, consequently, 
an increased immune response against the antigen. 
To summarize, the objective of this work was to design and develop a CS based nanoparticle with the 
capacity to co-deliver a peptide-based antigen with the immunostimulants pIC (as danger signal) and the 
PADRE peptide (to increase T helper responses). The ultimate goal has been the identification of 
potential synergistic effects among the three major components with regard to their ability to generate 
an effective antibody response. The expected low immunogenicity of the L2 peptide 1338aa allied with 
its great potential as antigen for an improved HPV vaccine makes it an excellent antigen model for the 
study of novel particle-based vaccines with intrinsic adjuvant activities. Even though the synergistic 
effect of the combination of the T helper peptides and pIC for immunization purposes has already been 
observed for a peptide-based antigen from HPV [23], this is, to the best of our knowledge, the first time 
that both molecules are combined in nanoparticles as an adjuvant system to solve the specific limitations 
of peptide-based antigens. 
2. Experimental Section 
2.1. Materials 
Peptide 1338aa and peptide PADRE were chemically synthesized (95% and 99% purity, respectively) 
by Genemed Synthesis (San Antonio, TX, USA). Amino acid sequence and physicochemical 
characteristics are described in Table 1. Polyinosinic-polycytidylic acid of low molecular weight (0.2–1 kB) 
(Poly (I:C)-LMW) was purchased from InvivoGen (San Diego, CA, USA). Ultrapure chitosan 
hydrochloride salt (Protasan UP Cl 113, Mw: 50,000–150,000 g/mol) was purchased from Novamatrix 
(Norway). Degree of deacetylation was confirmed by elemental analysis to be 75% ± 2%. Pentasodium 
tripolyphosphate (TPP), trehalose, TFA (Trifluoroacetic acid ≥99%), ammonium hydroxide and heparin 
were obtained from Sigma-Aldrich (Madrid, Spain). Chitosanase 10 U purified from Streptomyces griseus 
(C4163-01) was purchased from United States Biological (Salem MA, USA). SYBR Gold® and Nunc 
Maxisorp™ MicroWell™ flat-bottom 96-well plates were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA). HPLC-grade acetonitrile and water were purchased from Scharlab (Barcelona, 
Spain) and Fisher Chemical (Thermo Fisher Scientific, Waltham, MA, USA). 
Human serum adsorbed and peroxidase labeled anti-mouse IgG (H + L) goat antibody was purchased 
from KPL (Gaithersburg, MD, USA). The secondary anti-Rabbit IgG horseradish peroxidase linked 
whole antibody from donkey was purchased from Amersham (GE Healthcare Life Sciences, Little 
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Chalfont, UK). ABTS was acquired from Roche (Basel, Switzerland). Imject® Alum (aluminum 
hydroxide) was obtained from Pierce Biotechnology (Waltham, MA, USA). 
Table 1. Physicochemical characteristics of the peptides. 
Peptide Amino Acid Sequence MW Purity pI 
Charge at pH 








1973 99% 3.85 −4 −4 −4 −5 
MW: Molecular weight as provided by manufacturer; (Cha): Cyclohexylalanine; (D-Ala): D-Alanine;  
pI: Theoretical pI predicted by online software from SIB Swiss Institute of Bioinformatics [24]; Charge at pH: 
Charge calculated according to the method described in Appendix Equation (A1). 
2.2. Design and Preparation of CS and pIC Based Nanoparticles 
The nanoparticles were produced by the ionic gelation technique originally developed in our group [25] 
and extensively used for the association of peptides, proteins and pDNA [6,7,26–29]. According to this 
technique, the nanoparticles are formed spontaneously due to the ionic cross-linking of CS molecules by 
the TPP. In the current study, for the formation of the nanoparticles, pIC was also included in the TPP 
aqueous phase. In order to obtain a monodisperse population of nanometric particles with efficient pIC 
incorporation, different TPP and pIC concentrations were tested. The TPP concentrations were 0, 0.25, 
and 0.625 mg/mL while in the case of the pIC were 0.25, 0.625 and 1.25 mg/mL, with a constant volume 
of 0.2 mL. The CS concentration and volume were fixed at 1 mg/mL and 0.5 mL, respectively. The resulting 
nanoparticles were allowed to form for 30 min and then, they were isolated by ultracentrifugation at 
20,000 RCF, 4 °C for 2 h (Centrifuge 5430R, Eppendorf AG, Hamburg, Germany) on a glycerol bed. The 
supernatant was removed and the pellet was resuspended in 0.1 mL of ultrapure water. 
2.3. Physicochemical Characterization 
Particle size, polydispersity index (PdI) and derived count rate (DCR) were evaluated by Dynamic 
Light Scattering (DLS), and zeta-potential by Electrophoretic Light Scattering (ELS) using a Zetasizer 
Nano ZS90 (Malvern Instruments, Worcestershire, UK). The measurements were performed at 25 °C 
with a detection angle of 173°, in distilled water. The morphology of the nanoparticles was examined by 
transmission electron microscopy (TEM) (CM 12 Philips, Eindhoven, The Netherlands). The nanoparticles 
were placed on copper grids with Formvar films and stained with 2% (w/v) phosphotungstic acid 
solution. The grids were left overnight in an oven at 60 °C to dry and then observed with TEM.  
The solutions and formulation pH was determined with a Sartorius Docu-pH Benchtop Meters (Thermo 
Fisher Scientific). 
2.4. Evaluation of pIC Loading in Nanoparticles 
The association efficiency of pIC into the nanoparticles was calculated indirectly, from the amount 
of free pIC detected in the supernatant collected upon ultracentrifugation. The free pIC was determined 
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by absorbance at 260 nm (Abs 260 nm) with a NanoDrop 2000 (Thermo Fisher Scientific) and quantified 
by interpolation in a linear standard curve (R2 = 0.9988) produced with pIC solubilized in the supernatant 
of blank nanoparticles in a concentration range from 2.5 to 80 μg/mL. 
The association of pIC was confirmed by electrophoresis in a 1% agarose gel using a Sub-Cell GT 
96/192 electrophoresis system (Bio-Rad, Hercules, CA, USA). Briefly, the isolated nanoparticles were 
stained with SYBR Gold® and then 0.025 mL of formulation was added (equivalent to 8.4 μg pIC) to 
the agarose gel wells. After applying 90 V for 45 min, the gels were evaluated with an UV transilluminator 
(Molecular Imager® Gel Doc™ XR, Bio-Rad, CA, USA) and analyzed with Image Lab™ Software  
(Bio-Rad, Hercules, CA, USA). 
The reversibility of the pIC association was tested by incubating the nanoparticles with heparin 
(Sigma-Aldrich, Madrid, Spain) and verifying its release in an agarose gel [26]. In brief, fresh isolated 
nanoparticles and freeze dried nanoparticles were incubated in a 1.2 mg/mL heparin solution for 2 h at 
37 °C in order to have an excess of heparin in relation to the pIC (mass ratio pIC/heparin 1/3) and induce 
the competitive displacement of the pIC molecules by the anionic polysaccharide. 
In order to verify that pIC remained intact upon incorporation into the CS matrix, the nanoparticles 
were incubated with chitosanase (an enzyme capable of hydrolyzing the CS into oligosaccharides, 
releasing the associated pIC) [7,26]. For this, 0.1 mL of fresh isolated nanoparticles (0.4608 mg) were 
incubated with 1.1 U of chitosanase in a 50 mM acetate buffer pH 5.5, for 4 h at 37 °C under agitation. 
After incubation, an aliquot (0.019 mL) was taken and tested in a 1% agarose gel. This same protocol 
was also applied to freeze dried particles (described below) to verify pIC stability in the nanoparticles 
after the freeze drying process. 
2.5. Peptide Association to Nanoparticles 
Firstly, the 1338aa peptide was solubilized in sterile water at the concentration of 10 mg/mL, while 
the PADRE peptide, due to its higher hydrophobicity, was solubilized in a 0.07 M ammonium hydroxide 
solution to the final concentration of 5 mg/mL. The association of the peptides to the CS/TPP/pIC 
nanoparticles was achieved either by incorporation of the peptides into the TPP/pIC containing phase 
(Protocol A), during the nanoparticles’ formation process (Section 2.2.), or by their incubation with the 
preformed nanoparticles (Protocol B), as illustrated in Figure 1. 
In Protocol A, all components to be entrapped within the CS matrix, poly (I:C), PADRE peptide and 
1338aa peptide were incorporated into the aqueous phase containing TPP. The concentration of these 
ingredients in the aqueous phase was: 0.625 mg/mL for TPP, 0.25 mg/mL for poly (I:C), 0.125 mg/mL 
for PADRE peptide and 0.125 mg/mL for 1338aa peptide. The final pH of this phase upon dissolution 
of all these ingredients was 8.8. Then, a volume of 0.2 mL of this aqueous phase was added to a 0.5 mL 
volume of the CS phase (1 mg/mL, pH 4.80) and the mixture was maintained under magnetic stirring 
for 5 min to produce the formulation NP E. 
In Protocol B, the peptide was adsorbed onto the preformed nanoparticles. These nanoparticles were 
produced by mixing 0.2 mL of the aqueous phase containing TPP and pIC (0.625 and 0.25 mg/mL, 
respectively) with 0.5 mL of the CS phase (1 mg/mL). After the nanoparticles were formed, a 0.1 mL of 
1338aa peptide aqueous solution (0.25 mg/mL) containing the PADRE peptide (0.25 mg/mL; pH 9.6) 
or not (pH 6.4) was poured over 0.7 mL of the nanoparticle suspension (pH 5). The system was maintained 
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under magnetic stirring for 5 min and, then, the formulation was left to stand for 1 h at room temperature. 
The resulting nanoparticles were named as NP A2 and NP A1, depending on whether they included 
PADRE in their composition or not. After the incubation period, the nanoparticles were isolated by 
ultracentrifugation at 20,000 RCF, 4 °C for 2 h on a glycerol bed (Centrifuge 5430R, Eppendorf AG, 
Germany). An additional nanoparticle composition was produced according to the protocol used NP A2, 
but without pIC (NP C). The theoretical loading of each peptide with respect to the CS mass was 5% in 
all cases. 
 
Figure 1. Illustration of peptide-loading into nanoparticles either by encapsulation of both 
peptides to generate the formulation NP E (A); by adsorption of 1338aa or of 1338aa and 
PADRE to generate the formulation NP A1 and NP A2, respectively (B). Representation of 
both peptides, divided in their active part (1338aa sequence and PADRE sequence) and its 
six aspartic acid segment designed to promote their interaction with the CS amino groups. 
2.6. Evaluation of the 1338aa and PADRE Association 
To evaluate the peptide association efficiency, the loaded nanoparticles were first isolated by 
ultracentrifugation, as previously described. The supernatant was eliminated and the nanoparticles pellet 
was recovered and digested with chitosanase in the same conditions as reported above (Section 2.4).  
The peptide released after nanoparticle digestion was determined by an ultra-performance LC (UPLC) 
coupled with UV detection system (ACQUITY UPLC H-Class, Milford, MD, USA) using a reverse 
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phase Acquity UPLC BEH C18 column (1.7 um 130 Å 2.1 × 100 mm) and a gradient elution. The mobile 
phase A consisted of TFA 0.1% (v/v) aqueous solution and the mobile phase B of TFA 0.1% (v/v) in 
acetonitrile. Other UPLC conditions are described in Appendix Table A1. For the standard curve, the 
peptides were diluted in the digested matrix of nanoparticles (NP B) at concentrations between 3.125 
and 100 μg/mL. 
2.7. Freeze-Drying of Nanoparticles 
Lyophilization was conducted in a VirTis Genesis 25L lyophilizer (Model SQ EL-85, SP Scientific, 
Warminster, PA, USA). The samples were frozen overnight at −20 °C and then transferred to the 
lyophilizer. They underwent an initial drying step for 24 h at −35 °C at 2–10 millitorr (mtorr) followed 
by a secondary drying for another 24 h at 0 °C and finally a third step of 16 h at 20 °C at the same 
pressure. Trehalose was used as a cryoprotectant at different concentrations (0%, 2.5%, 5% and 10% 
w/v), while the nanoparticle concentration was evaluated at 42% and 25% (v/v). After freeze drying, loaded 
nanoparticles were reconstituted with ultrapure water (0.1 mL) in order to analyze their particle size and 
PdI. The same freeze-drying cycle was used to dehydrate the isolated formulations and determine the 
formulation process yield and the nanoparticle concentration by gravimetric analysis. 
2.8. Immunization Studies 
The ability of nanoparticles to induce an antibody response against the 1338aa peptide was assessed 
in 6- to 8-week-old female BALB/c mice obtained from the National Cancer Institute (NCI), housed and 
handled under specific pathogen-free conditions in the animal care facilities at the NCI, Bethesda. 
Groups of 5 mice were randomly assigned and immunized intramuscularly (i.m.) in the anterior thigh, 
with a first and second boost given on day 21 and 42, respectively. The immunization dose of 1338aa 
was 5 μg (0.05 mL). 
The control, alum-adsorbed antigen, was prepared according to the manufacturer’s specifications. 
Briefly, the Imject® Alum was agitated until complete homogenization of the dispersion and then it was 
added dropwise over a 1338aa solution in PBS, producing a final dispersion of alum salt and 1338aa at 
the concentration of 0.1 mg/mL. This dispersion was left under agitation for 1 h at room temperature 
before administration. As an additional control, the same formulation without pIC (NP C) was used. 
The blood samples (0.2 mL) were collected by retro-orbital bleeding at 0, 3, 6 and 8 weeks after the 
first vaccination. The animals were anesthetized (isofluorane 5% in oxygen vapor) before each immunization 
and blood sample collection. The blood samples were ultracentrifugated for 10 min at 14,926 RCF and 
then 0.05 mL of serum was collected. Serum IgG levels for 1338aa were determined for each sample by 
ELISA. For this purpose, Maxisorp® 96-wells were coated with 0.1 mL of the 1338aa peptide at 5 μg/mL 
in PBS and incubated overnight at 4 °C. After washing with PBS, the wells were blocked with 0.2 mL 
of 5% bovine serum albumin in carbonate-bicarbonate buffer for 2 h at 37 °C. After washing again with 
PBS, 0.1 mL of the respective serum, diluted 1:50 in PBS with 2% fetal bovine serum (FBS), was added 
and incubated 1 h at 37 °C. After new wash with PBS and 0.05% Tween 20, 0.1 mL of secondary 
antibody (goat anti-Mouse IgG (H + L) labeled with HPR) diluted 1:1000 in PBS with 1% FBS was 
added to the wells, and left incubating for 1 h at room temperature. Finally, the wells were washed again 
with PBS, and then the ABST substrate was added to the wells. After 40 min incubation, the absorbance was 
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determined in a microplate reader (405 nm, POLARstar OPTIMA, BMG-Labtech Gmbh, Ortenberg, 
Germany). All the washing and blocking steps were done with an automated microplate washer (ELx405 
Select Deep Well Microplate Washer, Biotek, Winooski, VT, USA). All serum samples were tested in 
duplicate. As positive control for the 1338aa peptide coating of the wells, HPV16 L2 peptide 17–36aa 
rabbit antiserum was used in a dilution of 1:1000 [13]. As secondary antibody, an anti-rabbit IgG was 
used in a dilution of 1:2000. 
3. Results and Discussion 
The objective of the present work was to design a nanocarrier, specifically adapted for the co-association 
of antigens and different types of immunostimulants. The final goal was to explore the synergistic effect 
of different adjuvant molecules assembled together in a nanostructure. With this idea in mind, three main 
components were chosen for the formation of the nanostructures: chitosan, known for its capacity to 
facilitate antigen presentation to the immune system when presented in a nanometric structure [6,7],  
poly (I:C), a potent immunostimulant, and a T-Helper peptide (PADRE). In addition, these nanoparticles 
were expected to protect poly (I:C) from degradation [30], and facilitate its delivery in the immune cells, 
where its receptor (TLR3) is located. To assess the value of this nanocomposition, a challenging HPV 
related peptide-based antigen (1338aa) was selected (Figure 1). This peptide was either adsorbed onto 
the nanoparticles surface, or incorporated within the nanoparticle structure. The key aspects of the 
development and characterization of these new nanostructures and the results of an exploratory in vivo 
efficacy assay are reported below. 
3.1. Design and Characterization of Chitosan-Poly (I:C) Based Nanoparticles 
The development process of the multicomponent nanoparticles consisted of several subsequent steps. 
The first step involved the entrapment of poly (I:C) into CS nanoparticles. Based on previous work from 
our group [25], a CS/TPP mass ratio of 4/1 and 8/1 was selected for the formation of the nanoparticles. 
The TPP is an ionic cross-linking agent that promotes the gelation of chitosan and facilitates the 
formation of well-defined spherical nanoparticles. The CS/pIC mass ratio tested was 4/2, 4/1 and 4/0.4, 
which is equivalent to a pIC theoretical loading of 10%, 25% and 50%, respectively, in relation to the 
total amount of CS used for particle preparation (Table 2). Simple complexes of CS and pIC, without 
TPP, were also produced as previously described [26]. The positive-to-negative charge (P/N) ratio, 
defined as the ratio between the maximum number of protonable primary amines in CS (based on a 75% 
deacetylation degree, as determined by elemental analysis) and the sum of negative phosphate groups 
from TPP and pIC is also presented in Table 2 for each composition. 
As shown in Table 2, the CS/TPP/pIC mass ratio 4/1/1 and 4/1/2 (25% and 50% pIC loading, 
respectively) led to the formation of aggregates or highly polydisperse particles. This could be related to 
the fact that the P/N ratio of these formulations was close to neutrality (1/1.13 and 1/0.95) and/or to the 
formation of additional complexation species, e.g., complexes of CS and p(I:C). In fact, in agreement 
with previous findings [25], the complexes formed by ionic interaction of CS and pIC without TPP 
presented a high PdI as compared with nanoparticles produced by ionic gelation of CS with TPP. The 
entanglement of the pIC in the gelled matrix of CS and TPP may provide a better entrapment of the 
polynucleotides in comparison to the simple electrostatic interaction between CS and pIC, as observed 
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previously for pDNA [26] and dsRNA [30]. Thus, the gelled nanostructure could be more adequate for 
preventing the premature release of pIC. This is a critical issue given the potential toxicity associated to 
the systemic release of pIC [20]. 
Table 2. Physicochemical characterization of Chitosan-Poly (I:C) nanoparticles at different 
mass ratios. 
CS/TPP/pIC P/N pIC (%) Size (nm) PdI ζ (mV) Derived Count Rate 
4/1/2 1/1.13 50 Aggr. - - - 
4/1/1 1/0.95 25 369 ± 27 0.5 +32 ± 3 108264 
4/1/0.4 1/0.85 10 284 ± 15 0.2 +41 ± 1 46537 
8/1/4 1/0.74 50 363 ± 14 0.3 +42 ± 2 64724 
8/1/2 1/0.56 25 290 ± 25 0.2 +43 ± 5 24955 
8/1/0.8 1/0.46 10 302 ± 23 0.2 +55 ± 3 10495 
8/0/4 1/0.35 50 350 ± 24 0.3 +49 ± 1 49503 
8/0/2 1/0.17 25 243 ± 8 0.3 +56 ± 1 19691 
8/0/0.8 1/0.07 10 172 ± 5 0.2 +56 ± 1 6064 
CS/TPP/pIC mass ratio: Mass ratio between chitosan, TPP and poly (I:C); P/N charge ratio: Charge ratio 
between the amine groups of CS and the sum of the phosphate groups of TPP and pIC; pIC Loading (%): 
Loading of poly (I:C) in particles in relation to the chitosan mass; PdI: Polydispersity Index; ζ: Zeta-potential. 
Results are presented as mean ± standard deviation (n = 4). 
Among the CS/TPP/pIC mass ratios tested, those consisting of 4/1/0.4 and 8/1/2 led to the formation 
of nanoparticles with an acceptable size (<300 nm) and PdI (<0.3). On the other hand, the yield of the 
nanoparticles formation process was much higher for the ratio 4/1/0.4 than for 8/1/2 (yield of 77 and 
47%, respectively). Therefore, the CS/TPP/pIC mass ratio 4/1/0.4 (from now on named NP B) was 
selected for further experiments. These nanoparticles exhibited a spherical shape (Figure 2) and a high 
positive surface charge (+41 mV). This positive charge, which indicates that pIC was conveniently 
entrapped within the chitosan matrix, is an important feature for the subsequent adsorption of the anionic 
peptides 1338aa and PADRE and also to facilitate nanoparticle uptake by antigen-presenting cells [31]. 
 
Figure 2. Morphology of Chitosan/TPP/Poly (I:C) nanoparticles (NP B) visualized by 
transmission electron microscopy. The scale bars correspond to 200 nm. 
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3.2. Association and Release of pIC from CS/TPP/pIC Nanoparticles 
As determined by spectrophotometry, the association efficiency of pIC in the selected mass ratio 
composition CS/TPP/pIC 4/1/0.4 was close to 100%. This high pIC association efficiency was further 
confirmed by agarose gel electrophoresis. The migration patterns presented in Figure 3 show the absence 
of bands corresponding to free pIC in the nanoparticles suspending medium (obtained upon centrifugation 
of the suspension) (well 7) or in the nanoparticle suspension (well 8). This high efficiency is in agreement 
with previous work showing the high capacity of CS/TPP nanoparticles for the association of DNA and 
dsRNA [26,30]. To verify if the pIC was firmly associated to the nanoparticles, the system was incubated 
with heparin, a strong polyanion that might compete for the CS amino groups and displace loosely 
attached polynucleotide material [32]. The results showed that after incubation with an excess of heparin 
(1.2 mg/mL), only a small amount of pIC migrated (well 9), which illustrates the high affinity of pIC 
towards CS/TPP nanoparticles. This is an important result as it is known that the cell extracellular matrix 
contains polyanions similar to heparin that might favor the dissociation of polynucleotides [33]. In order 
to assess the stability of the complexed pIC, the nanoparticles were digested with chitosanase to facilitate 
the release of pIC, which was then evaluated by agarose gel electrophoresis. The results showed that the 
migration pattern of the released pIC molecules was the same as that of the control pIC. Consequently, 
it can be concluded that pIC was firmly associated to the nanoparticles and could be released in an 
appropriate manner as a result of the polymer degradation. These results are in agreement with those 
previously reported showing the capacity of chitosan/TPP nanoparticles to deliver DNA [26] and dsRNA 
to different cells [30], including macrophages [34]. However, from our knowledge, this is the first report 
disclosing the potential of chitosan nanoparticles for the association of pIC as a strategy for enhancing 
the immunogenic response to the associated antigens.  
 
Figure 3. Agarose gel assay on pIC release from NP B (Chitosan/TPP/Poly (I:C) without 
peptides): (1) DNA Ladder; (2) 8 μg pIC; (3) 4 μg pIC; (4) 2 μg pIC; (5) 1 μg pIC;  
(6) 0.5 μg pIC in solution; (7) NP B Supernatant; (8) NP B Pellet; (9) NP B Pellet incubated 
with heparin; (10) NP B Pellet digested with chitosanase; (11) NP B Pellet freeze dried; (12) 
NP B Pellet freeze dried and incubated with heparin; (13) NP B Pellet freeze dried incubated 
with chitosanase. 
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3.3. Evaluation of the 1338aa and PADRE Peptide Association to CS/TPP/pIC Nanoparticles 
The peptides 1338aa and PADRE were designed to encode HPV16 L2 neutralizing and T-helper 
amino acid sequences, respectively. In addition to these active sequences, a segment of six aspartic acid 
molecules was also incorporated at the C-terminus region of both peptides (Table 1). This segment was 
intended to work as an electrostatic anchor for the positively charged chitosan molecules, thus leaving 
the active region of the peptide available for interaction with its specific receptors (Figure 1). Based on 
the calculation described in Appendix Equation (A1), at the formulation pH (5.74), the peptides are 
expected to present a high negative charge, as shown in Table 1, which would enable the electrostatic 
interaction with the positively charged nanoparticles (Table 2). 
Two different protocols were used for the association of the peptides to the nanoparticles in order to 
promote their localization, either inside (Protocol A) or on the surface of the nanoparticles (Protocol B) 
(Figure 1). The nanoparticles obtained by both protocols, presented a nanometric size and low PdI (Table 3). 
In both methods, the resulting peptide-loaded nanoparticles presented a positive surface charge, which in 
the case of the particles produced by the Protocol B indicates that their surface was not totally covered by 
the adsorbed peptide molecules. In Protocol A, the peptides were dissolved together with TPP and pIC 
and added to the CS phase to facilitate simultaneous 1338aa and PADRE entrapment within the 
nanoparticle matrix (loading efficiency of 67% and 71%, respectively) (Table 3). The basic pH of the 
TPP/pIC/peptides phase (pH 8.8) possibly increased the anionic character of the peptides (Table 1), 
thereby improving their interaction with CS. In Protocol B, the peptides were simply adsorbed onto the 
nanoparticle surface and, as expected, the L2 antigen association efficiency was lower (39%–50%) [26], 
although the PADRE association remained almost unaltered (75%). Interestingly, when the peptide 
1338aa was adsorbed onto the nanoparticles in combination with the PADRE peptide, it had higher 
association than added alone (50% and 39%, respectively) (Table 3). A possible cause for this could be 
that the combined solution of 1338aa and PADRE had a higher pH (9.6) than that of the 1338aa peptide 
alone (6.4). This higher pH results from the fact the PADRE was solubilized in a 0.07 M ammonium 
hydroxide. This could have increased the negative charge of 1338aa (Table 1) and, consequently, promote 
interaction with the positively charged CS. 
By digesting the nanoparticles and analyzing the released peptides by UPLC, it was also possible to 
verify that both peptides maintained their stability upon association to the nanoparticles (Appendix 
Figure A1). The mild formulation conditions probably contributed to the stability observed both for the 
pIC and peptides associated to the nanoparticles. In addition, all the formulations maintained their 
physicochemical characteristics for at least one year at 4 °C (Figure 4). 
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Table 3. Physicochemical characteristics and loading efficiency of Chitosan/TPP/Poly (I:C) 
nanoparticles (Chitosan/pIC) loaded with 1338a and PADRE peptides. 
Formulation Code Size (nm) PdI ζ (mV) 1338aa (%) PADRE (%) 
Chitosan/pIC without peptide (Blank) NP B 284 ± 15 0.2 +41 ± 1 N/A N/A 
Chitosan/pIC-1338aa Adsorbed NP A1 299 ± 23 0.2 +49 ± 5 39 ± 1 N/A 
Chitosan/pIC/PADRE-1338aa Adsorbed NP A2 274 ± 9 0.2 +47 ± 5 50 ± 5 75 ± 13 
Chitosan/pIC/PADRE-1338aa Encapsulated NP E 290 ± 28 0.2 +48 ± 4 67 ± 8 71 ± 3 
Chitosan/pIC-1338aa Adsorbed: Chitosan/TPP/Poly (I:C) nanoparticle with 1338aa adsorbed at surface; 
Chitosan/pIC/PADRE-1338aa Adsorbed: Chitosan/TPP/Poly (I:C) nanoparticle with PADRE and 1338aa 
adsorbed at surface; Chitosan/pIC/PADRE-1338aa Encapsulated: Chitosan/TPP/Poly (I:C) nanoparticle with 
PADRE and 1338aa encapsulated; Size: Particle size distribution; PdI: Polydispersity Index; ζ: Zeta-potential; 
1338aa Loading (%): Percentage of peptide 1338aa associated to the nanoparticle; PADRE Loading (%): 
Percentage of peptide PADRE associated to the nanoparticle. Loading values were obtained from the direct 
determination of the peptide released after the digestion of the nanoparticles with chitosanase. Results are 
presented as mean ± standard deviation (n = 3). 
 
Figure 4. Particle size distribution (Size) and polydispersity index (PdI) after one year  
storage at 4 °C in suspension; NP B: Chitosan/TPP/Poly (I:C) nanoparticles without 
peptides; NP A1: Chitosan/TPP/Poly (I:C) nanoparticles with 1338a adsorbed at surface;  
NP A2: Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa and PADRE adsorbed at surface; 
NP E: Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa and PADRE encapsulated. Results 
are presented as mean ± standard deviation (n = 3). 
3.4. Freeze-Drying of CS/TPP/pIC Nanoparticles 
In general, the dehydration of the nanoparticle formulations helps to prevent particle aggregation and 
degradation [35]. For this reason, the feasibility of freeze-drying the CS/TPP/pIC nanoparticles was 
explored. Trehalose was chosen as a cryoprotectant [35], and the influence of the formulation concentration 
(42% and 25% (v/v)) and the trehalose concentration (10%, 5% and 1% (w/v)) in the resuspension of 
the dried formulation was studied. The resulting powder cakes were resuspended with 0.1 mL of 
ultrapure water to provide for a final antigen concentration of 0.1 mg/mL. A 42% (v/v) nanoparticle 
concentration at 5% trehalose (w/v) generated an adequate cake, which could be easily resuspended. The 
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resuspended particles presented only a modest variation in size, PdI and zeta-potential (between 10% and 
15%), as shown in Figure 5. An additional positive effect of the developed freeze-drying method is that 
due to the final trehalose concentration (12%), the resuspended solution was close to isotonic. 
 
Figure 5. Comparison of the formulations in terms of particle size and polydispersity (A) 
and of zeta-potential (B) before and after freeze-drying and resuspension operation. Size: 
Size of the formulation before freeze-drying; Size F: Size after freeze-drying; PdI: Polydispersity 
of formulation before freeze-drying; PdI F: PdI after freeze-drying; ζ: Zeta-potential of 
formulation before freeze-drying; ζ F: Zeta-potential after freeze-drying; NP B: 
Chitosan/TPP/Poly (I:C) nanoparticles without peptides; NP A1: Chitosan/TPP/Poly (I:C) 
nanoparticles with 1338aa adsorbed at surface; NP A2: Chitosan/TPP/Poly (I:C) nanoparticles 
with 1338aa and PADRE adsorbed at surface; NP E: Chitosan/TPP/Poly (I:C) nanoparticles 
with 1338aa and PADRE encapsulated. Results are presented as mean ± standard deviation 
(n = 3). 
The stability of the pIC associated to the freeze-dried nanoparticles upon one week of storage at room 
temperature was analyzed by agarose gel electrophoresis (Figure 3). Similar to the fresh particles, the 
absence of the free pIC band in the gel indicates that the pIC remains firmly attached to the particle after the 
freeze-drying (well 11) even after incubation with heparin at 37 °C (well 12). Furthermore, upon 
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digestion of the nanoparticle with chitosanase, the pIC band became visible with a migration pattern and 
intensity (well 13) similar to those of the control (well 2). This indicates that these nanoparticles can 
efficiently protect the pIC from degradation during freeze-drying and upon storage in a dry powder form. 
After confirming the suitability of the freeze drying procedure for the pIC-containing nanoparticles, the 
peptide-loaded CS/TPP/pIC formulations were freeze-dried in the same conditions. The results showed 
that these formulations also preserved their physicochemical characteristics after resuspension, with only 
minor variation in size and zeta-potential (Figure 5). 
3.5. Immunization Studies 
A preliminary vaccination study was conducted to evaluate the influence of the different components 
and their organization on the ability of the nanoparticle to generate a humoral immune response. The 
formulations selected, presenting different 1338aa and PADRE arrangements were: nanoparticles with 
the peptide 1338aa alone adsorbed at the surface (NP A1), with the peptide 1338aa and PADRE both 
adsorbed at the surface (NP A2), and the nanoparticles with both peptides encapsulated (NP E). These 
formulations and also three controls, the alum-adsorbed antigen, nanoparticles without peptides (NP B) 
and nanoparticles with peptides but without pIC (NP C), were administered to mice by the intramuscular 
route and the IgG response was monitored for up to eight weeks (Figure 6). 
 
Figure 6. 1338aa peptide-specific IgG responses in diluted serum (1/50) of mice immunized 
with different formulations by intramuscular route. NP B: Chitosan/TPP/Poly (I:C) nanoparticles 
without peptides; NP C: Chitosan/TPP nanoparticles with 1338aa and PADRE adsorbed on 
their surface; NP A1: Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa adsorbed on their 
surface; NP A2: Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa and PADRE adsorbed 
on their surface; NP E: Chitosan/TPP/Poly (I:C) nanoparticles with 1338aa and PADRE 
encapsulated. (Number/5): Number of responsive mice in the total five mice per group. An 
O.D. four times higher than those of the control NP B (0.2) was considered a positive 
response. Results are presented as mean ± standard error of mean (n =5).  
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The O.D. values for IgG shown in Figure 6 indicate that alum was unable to enhance the immune 
response against the 1338aa peptide. On the other hand, peptide-loaded CS nanoparticles without pIC, 
known for their capacity to increase IgG responses against various protein antigens [6,7,27,29,36,37], 
failed to generate peptide-specific IgG responses. These results underline the difficulty in generating an 
immune response against poorly immunogenic peptides. With regard to the behavior of the formulation 
adjuvanted either with pIC, PADRE or both, the results were variable, exhibiting from one to three 
responding animals out of five immunized mice. Among the formulations tested, the composition 
containing both pIC and PADRE was capable of generating significant IgG levels in three out of five 
mice. These results suggest that both T helper and immunostimulant signals are required in order to 
achieve satisfactory antibody responses. In addition, the display of the peptide on the nanoparticle 
surface also appears to be critical. Indeed, the number of responding mice was greater when both peptides, 
1338aa and PADRE, were adsorbed rather than entrapped. 
The HPV L2 epitope 17–36aa [13], present in the peptide 1338aa, has already been tested in mice [38] 
although at a higher antigen dose (40 μg). In this study, it was observed that the Freund`s adjuvant  
was unable to stimulate an effective immune response against this peptide, confirming the low 
immunogenicity of this antigen. However, the conjugation of this peptide to other T Helper peptide (P25) 
and to the immunostimulant Pam2Cys (a TLR2 agonist) was very effective at inducing peptide-specific 
IgG responses. The comparison of these previous data with those obtained in the current study led us to 
formulate different hypotheses. First, there is the possibility that either the antigen (17–36aa) or the 
immunostimulants (P25 and Pam2Cys), or their combination were more appropriate for enhancing the 
immune response. In this regard, it is important to keep in mind that, although sharing the same epitope, 
the peptide 1338aa presents a longer amino acid chain and an additional six aspartic segment in the  
C-terminus region, which could potentially lead to a different processing and presentation by the immune 
cells [3]. A second hypothesis is that the interactions of 1338aa with the nanoparticle preclude an 
effective interaction with the B cell receptors. A third possibility is that the conjugation of the T helper 
peptide to the antigen facilitates induction of T helper functions. 
The poor B cell immunogenicity of peptide-based antigens has been associated, among other factors, 
with their inability to establish a highly repetitive epitope pattern, which results in the limited activation 
of naive B cells after engagement of their cell surface immunoglobulins [39]. It was hypothesized that 
the adsorption of the peptide 1338aa onto the surface of the nanoparticles would display the target 
antigen in a repetitive pattern on a nanometric structure, resembling a virus. This hypothesis was partially 
confirmed by the higher antibody response elicited by the prototypes with adsorbed antigen (NP A2), as 
compared to the prototypes entrapping the same (NP E). However, further improvements in the 
presentation of the peptide epitopes can be envisioned. As the target epitope of the peptide was connected 
directly with the six aspartic segments used for adsorption to the nanoparticle, it is possible that part of 
the active region became embedded in the nanoparticle matrix and hindered its recognition by the B cell 
receptors. The addition of a generic peptide spacer between the particle binding motif and the target 
peptide might overcome this problem and provide for a more efficient presentation of the target peptide 
to B cells. It could also be interesting to examine whether including PADRE and the target antigen in a 
single peptide would increase the T helper response and thereby increase antibody responses. Furthermore, 
while CS/TPP nanoparticles have demonstrated capacity for sustained release of proteins [7,27], the 
release profile with the peptides used herein has not been studied, and should be explored in detail in 
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further studies. Finally, according to the data presented, and in agreement with previous studies [26,40], 
the pIC is firmly associated to the nanoparticles and so the timing of its release may not be optimal for 
immune activation. As indicated previously, the introduction of pIC in the nanoparticles was expected 
to potentiate DC maturation [14] under the assumption that it would be released in endocytic vesicles 
along with the bound peptides. It has already been observed that for an optimal immune response with 
pIC, it is important that its delivery occurs simultaneously with that of the antigen of interest [41]. On 
the other hand, it has been recently suggested that the association of immunostimulants with CS 
nanosystems might prevent their interaction with the target [42]. Such hypothesis should be clarified in 
further experiments in order to improve the adjuvant effect of the developed system.  
Therefore, this study illustrates the technical feasibility of producing CS-based nanoparticles vaccines 
that incorporate peptide-based antigens in conjunction with immunostimulatory molecules, and provides 
insight into the complexity of the engineering process. A larger array of CS nanoparticles that 
incorporate different peptide and immunostimulant combinations and that vary in their structural 
organization and size will need to be developed in order to fully assess the value of this nanotechnology 
platform for generating effective peptide-based vaccines.  
4. Conclusions 
Here, we report for the first time, a chitosan nanostructure designed to co-deliver a TLR3 agonist 
(Poly (I:C)) and a T-helper peptide (PADRE) as adjuvant system for a HPV-derived peptide antigen 
(1338aa). These nanoparticles are produced by ionic gelation, a mild and gentle method, which permits 
by subtle modifications of the formulation procedure, either the encapsulation or the adsorption of the 
target peptides. The capacity of combining different materials (polysaccharides, polynucleotides and 
peptides) in the form of nanoparticles, and the possibility to freeze-dry them highlights the versatility of 
this system and opens the possibility of integrating other immune stimulants. The ability of these 
nanoparticles to induce an immune response towards a particularly poorly immunogenic antigen is in 
contrast to the low efficacy observed in the same study using alum salts adjuvant. In conclusion, the 
preliminary data presented here shows the potential of these nanoparticles as combined antigen/adjuvant 
structures to induce antibody responses to peptide antigens. 
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Appendix 
Table A1. UPLC conditions and peptide retention times. 
Gradient Additional Features Retention Time (min) 
Time (min) Phase A Phase B Flux (mL/min) 0.2 1338aa in dig. 4.674 
0 80 20 Wavelength Abs (nm) 280 PADRE in dig. 4.927 
1.50 80 20 Column Temp. (°C) 35 °C   
1.51 55 45 Filter time Constant Normal   
3.00 80 20 Volume injected (uL) 5   
1338aa in dig.: 1338aa dissolved in Chitosan/TPP/Poly (I:C) nanoparticle digested matrix; PADRE in dig.: 
PADRE dissolved in Chitosan/TPP/Poly (I:C) nanoparticle digested matrix. 
Equation (A1). Calculation of the peptides charge at specific pH 
Calculation was realized with the following equation: 
Z = ∑i Ni (10pKai/(10pH + 10pKai)) – ∑j Nj (10pH/(10pH + 10pKaj)) 
in which Z represents the net charge of the peptide sequence, Ni the number of arginine, lysine and 
histidine residues and the N-terminus, and pKai, their pKa. The Nj represents the number of aspartic 
acid, glutamic acid, cysteine and tyrosine residues and C-terminus, and the pKaj, their pKa. Note: In both 
predictions, the non-standard residue ciclohexylalanine had to be ignored and the D-Alanine was replaced by 
the L-Alanine for calculation purposes, which increases the error. However, both amino acids are neutral 
so the influence in the pI and charge according pH should be negligible. On the other hand, the aspartic 
tail should always be quite dominant in terms of peptide charge properties. 
 
Figure A1. Cont. 




Figure A1. Comparison between UPLC peaks from digested blank nanoparticles and 
peptide-loaded nanoparticles, and the free PADRE and 1338aa peptides in digested nanoparticle 
matrix. Comparison between UPLC peaks of digested peptide-loaded nanoparticles (A) 
encapsulated (B) surface adsorbed) with blank nanoparticles (C) and with free PADRE and 
1338aa peptides in digested nanoparticle matrix as controls (D); *: Peaks from residues of 
digested nanoparticles; **: Peak from PADRE peptide; ***: Peak from 1338aa peptide. 
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